Alternatives to Klisyri If You Can't Fill Your Prescription

Klisyri (tirbanibulin) is a highly convenient actinic keratosis treatment — just 5 days of once-daily application. But when it's hard to find or out of reach financially, the good news is that there are several effective FDA-approved alternatives. Here's a thorough breakdown of your options, their costs, how they work, and who might benefit most from each one.

Why Patients Look for Klisyri Alternatives

The most common reasons patients seek Klisyri alternatives include:

Klisyri is not stocked at their local pharmacy

Insurance requires step therapy (trying other drugs first)

The retail price (~$1,900) is prohibitive even with coupons

Medicare/Medicaid patients cannot use the manufacturer savings card

If any of these apply to you, talk to your dermatologist about the following alternatives. Note that many insurers actually require patients to try these first before approving Klisyri coverage.

Alternative 1: Fluorouracil (5-FU) Cream — The Gold Standard

Fluorouracil (5-FU) topical cream is one of the oldest and most thoroughly studied AK treatments. Available as Efudex (5%), Carac (0.5%), and Tolak (4%), as well as numerous generics, it works by blocking DNA synthesis in rapidly dividing precancerous cells.

Dosing: Applied once or twice daily for 2–4 weeks (longer course than Klisyri)

Efficacy: Complete clearance rates of approximately 49% (5% formulation) — comparable to Klisyri's 44–54%

Cost: Generic 5-FU cream costs approximately $30–$80 with a coupon — a fraction of Klisyri's price

Downside: More significant skin reactions (redness, crusting, inflammation) that can be uncomfortable for 2–4 weeks

5-FU is widely considered the most effective long-term option for AK field treatment and is almost universally available at pharmacies. A NEJM study showed 5-FU had the best sustained clearance compared to imiquimod, MAL-PDT, and ingenol mebutate at 12 months.

Alternative 2: Imiquimod Cream — Immune Modulator Approach

Imiquimod (brand: Aldara 5%, Zyclara 3.75%) works by stimulating the immune system — specifically toll-like receptor 7 — to attack precancerous cells. It's a completely different mechanism from Klisyri.

Dosing: 3 times per week for 4 weeks (5% formulation) or once daily for 2-week cycles (3.75% formulation)

Efficacy: Complete clearance rates of ~25–34% (3.75%) to ~50% (5% formulation)

Cost: Generic imiquimod ~$30–$80 per course

Advantage: May provide immune memory, potentially reducing future AK development

Alternative 3: Diclofenac 3% Gel — Gentlest Option

Diclofenac 3% gel (brand: Solaraze) is an NSAID-based topical AK treatment. It is the most well-tolerated of all the topical options, with minimal skin irritation.

Dosing: Applied twice daily for 60–90 days (significantly longer course)

Efficacy: Complete remission in ~28% of patients — lower than Klisyri but well-tolerated

Cost: Generic diclofenac sodium gel is widely available; most Medicare and insurance plans cover it

Best for: Patients who cannot tolerate the skin reactions from 5-FU or imiquimod

Alternative 4: Cryotherapy — In-Office Procedure

Cryotherapy (liquid nitrogen freezing) is a procedure performed in your dermatologist's office. It's best for isolated, individual lesions rather than field treatment. It doesn't require a prescription to fill and results are immediate. Studies show combining cryotherapy with topical treatment (like tirbanibulin) can improve outcomes even further.

Comparing Klisyri to Its Alternatives at a Glance

Klisyri: 5-day course, 44–54% clearance, ~$1,900 retail / $25 with copay card

Fluorouracil (5-FU): 2–4 week course, ~49% clearance (5%), $30–$80 generic

Imiquimod: 4-week course, 25–50% clearance, $30–$80 generic

Diclofenac gel: 60–90 day course, ~28% clearance, widely covered by insurance

Still Want Klisyri? Here's How to Keep Looking

If you still prefer Klisyri, don't give up. Use medfinder to have pharmacies in your area contacted on your behalf. Also read our full guide on why Klisyri is hard to find for more context on the availability issue.